AR103622A1 - PHARMACEUTICAL FORMULATION - Google Patents
PHARMACEUTICAL FORMULATIONInfo
- Publication number
- AR103622A1 AR103622A1 ARP160100330A ARP160100330A AR103622A1 AR 103622 A1 AR103622 A1 AR 103622A1 AR P160100330 A ARP160100330 A AR P160100330A AR P160100330 A ARP160100330 A AR P160100330A AR 103622 A1 AR103622 A1 AR 103622A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- pharmaceutical formulation
- liquid pharmaceutical
- antibody
- formulation according
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicación 1: Una formulación farmacéutica líquida que comprende un anticuerpo como ingrediente activo, y glicina y sacarosa. Reivindicación 10: Una formulación farmacéutica líquida de acuerdo con cualquiera de las reivindicaciones anteriores, caracterizada porque el anticuerpo es un anticuerpo humanizado o humano. Reivindicación 11: Una formulación farmacéutica líquida de acuerdo con cualquiera de las reivindicaciones anteriores, caracterizada porque el anticuerpo comprende: a) una cadena ligera que comprende CDR1, CDR2 y CDR3 tal como se define en la SEQ ID Nº 1, SEQ ID Nº 2 y SEQ ID Nº 3, respectivamente; y b) una cadena pesada que comprende CDR1, CDR2, y CDR3 tal como se define en la SEQ ID Nº 4, SEQ ID Nº 5 y SEQ ID Nº 6, respectivamente. Reivindicación 12: Una formulación farmacéutica líquida de acuerdo con cualquiera de las reivindicaciones anteriores, caracterizada porque el anticuerpo comprende una cadena ligera variable tal como se define en la SEQ ID Nº 7 y una cadena pesada variable tal como se define en la SEQ ID Nº 11.Claim 1: A liquid pharmaceutical formulation comprising an antibody as active ingredient, and glycine and sucrose. Claim 10: A liquid pharmaceutical formulation according to any of the preceding claims, characterized in that the antibody is a humanized or human antibody. Claim 11: A liquid pharmaceutical formulation according to any of the preceding claims, characterized in that the antibody comprises: a) a light chain comprising CDR1, CDR2 and CDR3 as defined in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 3, respectively; and b) a heavy chain comprising CDR1, CDR2, and CDR3 as defined in SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6, respectively. Claim 12: A liquid pharmaceutical formulation according to any of the preceding claims, characterized in that the antibody comprises a variable light chain as defined in SEQ ID No. 7 and a variable heavy chain as defined in SEQ ID No. 11 .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP160100330A AR103622A1 (en) | 2016-02-05 | 2016-02-05 | PHARMACEUTICAL FORMULATION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP160100330A AR103622A1 (en) | 2016-02-05 | 2016-02-05 | PHARMACEUTICAL FORMULATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103622A1 true AR103622A1 (en) | 2017-05-24 |
Family
ID=58941291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100330A AR103622A1 (en) | 2016-02-05 | 2016-02-05 | PHARMACEUTICAL FORMULATION |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR103622A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
-
2016
- 2016-02-05 AR ARP160100330A patent/AR103622A1/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR132864A2 (en) | AN ANTIBODY THAT SPECIFICALLY BINDS TO HUMAN α-SYNUCLEIN, A HUMANIZED ANTIBODY, A PHARMACEUTICAL FORMULATION COMPRISING THE ANTIBODY, AND THE USE OF THE ANTIBODY | |
| CO2019007844A2 (en) | Novel human transferrin receptor antibody capable of penetrating the blood brain barrier | |
| DOP2021000022A (en) | HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES | |
| PE20190970A1 (en) | ANTI-CD40 ANTIBODIES AND THEIR USES | |
| CO2019009680A2 (en) | Anti-gprc5d antibody and molecule comprising the antibody | |
| ECSP18043564A (en) | BI-SPECIFIC MOLECULES THAT HAVE IMMUNOREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME | |
| CO2019007823A2 (en) | Anti-cd3 antibody and molecules that comprise the antibody | |
| PE20180927A1 (en) | LAG-3 BINDING MOLECULES AND METHODS OF USE OF THEM | |
| AR117911A2 (en) | ANTI-158P1D7 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF, DRUG-ANTIBODY CONJUGATE, PHARMACEUTICAL COMPOSITION AND ITS USES | |
| MX2020008683A (en) | Antibody variable domains targeting cd33, and use thereof. | |
| PE20161210A1 (en) | ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE | |
| CR20170600A (en) | FACTOR X1 ANTIBODIES AND METHODS OF USE | |
| PE20142407A1 (en) | FORMULATION OF ANTIBODIES | |
| MX2018015393A (en) | Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof. | |
| ES2687282T3 (en) | ANTI-CD134 (OX40) humanized antibodies and their uses | |
| PE20161571A1 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
| MX2022011002A (en) | HUMANIZED OR CHIMERIC DIFFERENTIATION GROUP 3 (CD3) ANTIBODIES. | |
| AR104250A1 (en) | ANTI-NOTCH4 HUMAN ANTIBODY | |
| AR109715A1 (en) | ANTI-CD27 ANTIBODIES | |
| PE20181805A1 (en) | COMPOSITIONS AND ANTI-TIM-3 ANTIBODIES | |
| CL2016000324A1 (en) | Monoclonal antibodies that specifically bind to the plasminogen activator inhibitor type 1 (pai-1); and use to prepare a useful medicine to restore plasmin generation or treat a condition caused by increased levels of pai-1 or increased sensitivity to pai-1. | |
| PE20171180A1 (en) | ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE | |
| PE20170665A1 (en) | HUMANIZED ANTI-TAU ANTIBODIES | |
| AR102594A1 (en) | ANTI-IL-1b ANTIBODIES AND METHODS OF USE | |
| EA201691473A1 (en) | BISPECIFIC ANTI-IL-13 / IL-17 ANTIBODIES AND THEIR APPLICATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |